Extended Data Fig. 7: SERCA2a levels negatively correlate with increased Smurf1 and Hrd1 levels in human heart failure samples.
From: p22phox prevents the oxidation of SERCA2a and stabilizes it in the heart
(a–f) Human heart samples obtained from non-heart failure (non-HF) (donors) and heart failure (HF) patients (recipients) were analyzed by immunofluorescence and immunoblotting. (a) Representative immunofluorescence staining of non-heart failure (non-HF) (donors) and heart failure (HF) patients with SERCA2a antibody (Red fluorescence) and blue DAPI (nucleus). Scale bar = 200 µm. (b) Quantification of the relative SERCA2a fluorescence intensity in non-heart failure (non-HF, n = 7) (donors) and heart failure (HF, n = 6) patients. (c) Immunoblot of lysates from non-heart failure (non-HF) (donors, n = 7) and heart failure (HF) patients (recipients, n = 7) with dilated cardiomyopathy (DCM, n = 4) or ischemic cardiomyopathy (ICM, n = 3) showing SERCA2a, Hrd1 and Smurf1 levels, with GAPDH as loading control. (d–f) Quantification of indicated protein levels as the ratio to GAPDH, compared between donors and recipients. All bar graphs are represented as mean + SE. The statistical significance was determined with unpaired Student’s t test (2 tailed) (b) and the Mann Whitney test (2 tailed) (d–f).
